CRISPR-Cas9-Mediated Correction of TSC2 Pathogenic Variants in iPSCs from Patients with Tuberous Sclerosis Complex Type 2
The CRISPR Journal · 01.02.2025 · 8 (1) · 60-70
DOI: 10.1089/crispr.2024.0079 ↗Kurz gefasst
Fachartikel in der Zeitschrift The CRISPR Journal, online erschienen am 14.02.2025. Verfasst von Gongbo Guo und 7 weiteren Autor:innen. Beteiligte Einrichtung: The Steve and Cindy Rasmussen Institute for Genomic Medicine, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, US…. Hauptthemen laut MEDLINE: Tuberous Sclerosis Complex 2 Protein, CRISPR-Cas Systems, Tuberous Sclerosis, Induced Pluripotent Stem Cells. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 42 Literaturangaben.
Abstract (Originalsprache)
Tuberous sclerosis complex (TSC) is an autosomal dominant disorder caused by mutations in either the TSC1 or TSC2 genes. Though TSC causes the formation of nonmalignant tumors throughout multiple organs, the most frequent causes of mortality and morbidity are due to neurological complications. In two-thirds of cases, TSC occurs sporadically and TSC2 pathogenic variants are approximately three times more prevalent than TSC1 pathogenic variants. Here, we utilized CRISPR-Cas9-mediated homology directed repair in patient induced pluripotent stem cells (iPSCs) to correct two types of TSC2 pathogenic variants generating two isogenic lines. In one line, we corrected a splice acceptor variant (c.2743-1G>A), which causes the skipping of coding exon 23 and subsequent frameshift and introduction of a stop codon in coding exon 25. In the second line, we corrected a missense variant in coding exon 40 within the GTPase-activating protein domain (c.5228G>A, p.R1743Q). The generation of TSC2 patient iPSCs in parallel with their corresponding CRISPR-corrected isogenic lines will be an important tool for disease modeling applications and for developing therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- The Steve and Cindy Rasmussen Institute for Genomic Medicine, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA.
- Division of Hematology, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA.
- Department of Pediatrics, The Ohio State University College of Medicine, Columbus, Ohio, USA.
- Department of Pathology, The Ohio State University, Columbus, Ohio, USA.
- Department of Neuroscience, The Ohio State University, Columbus, Ohio, USA.
ORCID-Profile: Mark E Hester
Zitieren
APA
Guo, G., Moser, M., Chifamba, L., Julian, D., Teierle, S., Rajappa, P., Miller, C., & Hester, M. E. (2025). CRISPR-Cas9-Mediated Correction of TSC2 Pathogenic Variants in iPSCs from Patients with Tuberous Sclerosis Complex Type 2. The CRISPR Journal, 8(1), 60-70. https://doi.org/10.1089/crispr.2024.0079
Vancouver
Guo G, Moser M, Chifamba L, Julian D, Teierle S, Rajappa P, et al. CRISPR-Cas9-Mediated Correction of TSC2 Pathogenic Variants in iPSCs from Patients with Tuberous Sclerosis Complex Type 2. The CRISPR Journal. 2025;8(1):60-70. doi:10.1089/crispr.2024.0079
BibTeX
@article{Guo2025,
author = {Guo, Gongbo and Moser, Morgan and Chifamba, Lincoln and Julian, Dominic and Teierle, Samantha and Rajappa, Prajwal and Miller, Cecelia and Hester, Mark E},
title = {CRISPR-Cas9-Mediated Correction of TSC2 Pathogenic Variants in iPSCs from Patients with Tuberous Sclerosis Complex Type 2},
journal = {The CRISPR Journal},
year = {2025},
volume = {8},
number = {1},
pages = {60--70},
doi = {10.1089/crispr.2024.0079}
}
EUVIMED